1. Novel Agents for the Treatment of Low/Intermediate Risk Myelodysplastic Syndromes

2. Risk Stratification in MDS

3. MDS Risk Assessment: IPSS vs IPSS-R

4. Risk Assessment Remains a Challenge

5. Link Between Mutations and Comorbidities

6. Epidemiology of MDS[a]

7. Not All Patients Require Treatment

8. Use of Supportive Care Is Individualized

9. Treatment of Anemia in Lower-Risk MDS

10. Use of Lenalidomide in Patients with MDS

11. Luspatercept: A Novel ESA

12. Imetelstat: A First-in-Class Telomerase Inhibitor

13. Hypomethylating Agents in Lower-Risk MDS

14. Other Novel Strategies in MDS

15. Abbreviations

16. Abbreviations (cont)